WO2003045435A1 - Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs - Google Patents

Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs Download PDF

Info

Publication number
WO2003045435A1
WO2003045435A1 PCT/IB2002/004743 IB0204743W WO03045435A1 WO 2003045435 A1 WO2003045435 A1 WO 2003045435A1 IB 0204743 W IB0204743 W IB 0204743W WO 03045435 A1 WO03045435 A1 WO 03045435A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutical composition
formula
formulations
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2002/004743
Other languages
French (fr)
Inventor
Roger Nelson Kimball
Renuka Devi Reddy
Evgenyi Yur'evich Shalaev
Simon Edward Blanchflower
Brian Scott Bronk
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020047008097A priority Critical patent/KR100621291B1/en
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to BRPI0214583A priority patent/BRPI0214583B1/en
Priority to DE60228749T priority patent/DE60228749D1/en
Priority to IL16185102A priority patent/IL161851A0/en
Priority to MXPA04003724A priority patent/MXPA04003724A/en
Priority to NZ532208A priority patent/NZ532208A/en
Priority to CA002468708A priority patent/CA2468708C/en
Priority to AU2002348986A priority patent/AU2002348986B2/en
Priority to EP02781499A priority patent/EP1448234B1/en
Priority to JP2003546936A priority patent/JP4689959B2/en
Priority to DK02781499T priority patent/DK1448234T3/en
Priority to EA200400489A priority patent/EA008503B1/en
Publication of WO2003045435A1 publication Critical patent/WO2003045435A1/en
Priority to IS7214A priority patent/IS7214A/en
Priority to IL161851A priority patent/IL161851A/en
Priority to TNP2004000097A priority patent/TNSN04097A1/en
Priority to HR20040487A priority patent/HRP20040487A2/en
Priority to NO20042271A priority patent/NO334818B1/en
Priority to HK05104040.7A priority patent/HK1071292A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • This invention relates to stable lyophilized formulations containing an antibacterial alkali metal salt of a cephalosporin compound, Compound I, wherein M + is a cation, Na + , K + or Li + (hereinafter "Compound I").
  • the invention relates to stable lyophilized formulations of Compound I, wherein M + is Na + , ⁇ 6R,7R)-7- t[(2Z)-(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-8-oxo-3-[(2S)-tetrahydro-2- furanyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt.
  • the invention also relates to aqueous formulations of Compound I.
  • the invention is also directed to methods for treating bacterial infections in dogs and cats by administering a compound of Formula I.
  • Cephalosporins are widely used and therapeutically important antibiotics.
  • the compounds of Formula I are broad spectrum cephalosporin antibacterials and are, therefore, useful in the treatment of bacterial infections in animals. (US 6,020,329, Col. 1 , lines 13-14).
  • Compound I is targeted for dogs and cats with indications for treatment of bacterial infections of the skin, soft tissue, periodontal and urinary tract.
  • Cephalosporins may be somewhat stabilized within a certain pH range. The optimum pH range varies widely and is unpredictable for different classes of cephalosporins, requiring experimentation and stability tests.
  • Nassar et al. U.S. Pat. No. 5,401 ,842
  • Cephalothin has a broad stability range from a pH of between 2 to 8.
  • Cepharadine stabilizes at a more acidic pH between 1 to 5.
  • Cefotaxime Stability for Cefotaxime is achieved in the pH range of 3 to 7. (K.A. Connors, et al. Chemical Stability of Pharmaceuticals, John Wiley & Sons, New York, 1986, p305). In some cases, cephalosporin formulations were stabilized by crystallization and lyophilization. For example, Gotschi, U.S. Pat. No. 5,138,066, describes formulations for parenteral administration as lyophilizates or dry powders for dilution with pharmaceutical carriers such as water or isotonic saline.
  • cephalosporins may be stabilized by addition of a variety of different sugars. Whether a certain sugar will stabilize a particular cephalosporin, however, is unpredictable. Furthermore, the ratio of sugar to cephalosporin to achieve optimum stability is also unpredictable.
  • Shamblin et al. disclose that the stability of amorphous cefoxitin sodium was improved by a factor of two when co-lyophilized with sucrose. The stability of cefoxitin was not affected, however, when co-lyophilized with trehalose.
  • S.L. Shamblin, B.C. Hancock, M.J.Pikal The Chemical Stability of Amorphous Cefoxitin Sodium in the Presence of Glassy Stabilizers, AAPS Pharm. Sci. Vol. I, Issue 4, 1999.
  • Hirai et al. U.S. Patent No. 4,418,058, disclose that an excess amount, greater than 1 :1 , of a variety of different sugars or sugar alcohols adversely affected chemical stability of cephalosporins. Good stabilizing results were obtained, however, when the amount of added sugar or sugar alcohol was 0.1 to 1 sugar/cephalosporin.
  • the invention provides a pharmaceutical composition comprising a compound of Formula I,
  • M + is Na + , K + or Li + , and an aqueous diluent, wherein the composition has a pH in the range of 5.0 to 8.0.
  • the compound of Formula I is amorphous (6f?,7 ?j-7-[[(22)-(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-8-oxo-3-[(2S)- tetrahydro-2-furanyl]-5-thia-1-azabicyclo[4.2.b]oct-2-ene-2-carboxylic acid, monosodium salt.
  • M + is Na + and the pH is 6.0 to 7.5.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable buffer.
  • the buffer is carbonate, phosphate, citrate or acetate, and the pH within a range of 6.0 to 7.5.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable bulking agent.
  • the bulking agent is selected from sugars, polyalcohols, amino acids, polymers, polysaccharides or inorganic salts.
  • the sugars are selected from glucose, maltose, sucrose and lactose; the polyalcohols are sorbitol or mannitol; the amino acid is glycine; the polymer is polyvinylpyrrolidone; the polysaccharide is dextran; and the inorganic salts are sodium or potassium phosphates or sodium chloride.
  • the composition has a bulking agent/compound of Formula I ratio greater than 1.0, but less than 100.
  • the ratio is greater than 1 , but less than
  • the bulking agent is sucrose and the composition has a sucrose/compound of Formula I ratio of 3.
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I,
  • M + is Na + , K + or Li + , an aqueous diluent and a pharmaceutically acceptable bulking agent.
  • the bulking agent is selected from sugars, polyalcohols, amino acids, polymers, polysaccharides or inorganic salts.
  • the sugar is selected from glucose, maltose, sucrose or lactose; the polyalcohols are sorbitol or mannitol; the amino acid is glycine; the polymer is polyvinylpyrrolidone; the polysaccharide is dextran; and the inorganic salts are sodium or potassium phosphates or sodium chloride.
  • the composition has a bulking agent/compound of Formula I ratio of greater than 1 , but less than 10.
  • M + is Na + and the bulking agent is sucrose, wherein the composition has a sucrose/compound of Formula I ratio of 3.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable buffer. In a preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable preservative.
  • the preservative is methylparaben, propylparaben, m-cresol, benzalkonium chloride, benzethonium chloride or benzyl alcohol, or a combination of two or more thereof.
  • the preservative is a combination of either (a) methylparaben, propylparaben and benzyl alcohol; or (b) methylparaben and m- cresol.
  • the pharmaceutical composition further comprises a citrate buffer.
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I,
  • M + is Na +
  • M + is Na +
  • the buffer is citrate;
  • the preservative is methylparaben, propylparaben, m-cresol, benzalkonium chloride, benzethonium chloride or benzyl alcohol or a combination of two or more thereof; and the optional bulking agent is sucrose.
  • the pharmaceutical composition comprises a compound of Formula I, prepared by lyophilizing the pharmaceutical composition as described above.
  • the invention is directed to a kit comprising a) A therapeutically effect amount of a lyophilized pharmaceutical composition comprising a compound 1 of Formula I;
  • An aqueous pharmaceutically acceptable diluent b) An aqueous pharmaceutically acceptable diluent; and c) A first and second container means for containing the composition (1) and the diluent (2), wherein the first container is adapted to receive the diluent from the second container.
  • the invention is directed to a method of treating or preventing a condition caused by a bacterial infection in dogs and cats, comprising administering a therapeutically effective amount of a compound of Formula I
  • the invention is directed to a method of treating or preventing a condition caused by a bacterial infection in dogs and cats, comprising administering a therapeutically effective amount of the composition described above.
  • the condition is a skin, soft tissue or urinary tract bacterial infection.
  • condition or infection is caused by or complicated by Gram positive or Gram negative bacteria.
  • the term "about,” as used herein, is defined as a pH of 0.5 above or below the designated upper and lower pH units.
  • aqueous pharmaceutically acceptable diluent means water or other pharmaceutically acceptable aqueous solutions containing one or more pharmaceutically acceptable excipients for use in making the compositions of the invention (e.g. isotonic solution of sodium chloride, water for injection with ethanol or phosphate, acetate or citrate buffer, and water for injection with benzyl alcohol).
  • Na + is defined as a sodium cation.
  • K + is defined as a potassium cation.
  • Li + is defined as a lithium cation.
  • composition encompasses, inter alia, (1) solutions comprising Compound I or (2) dry lyophilized residues of such solutions.
  • the solutions may contain one or more optional agents which aid in stabilizing dissolved Compound I and/or that facilitate re-dissolution, upon reconstitution of the lyophile created after lyophilizing solution (1).
  • optional agents include, inter alia, bulking agents, preservatives, and buffers, as further disclosed herein.
  • Compound I is limited to the pharmaceutically acceptable alkali metal salts of Compound I, wherein M + is Na + , K + or Li + , and in particular, includes Compound I, (6 ?,7f? 7-[[(22)-(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-8- oxo-3-[(2S)-tetrahydro-2-furanyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt), wherein M + is Na + .
  • lyophilization means the process of f reeze-drying a composition as known in the art. "Lyophilized” and “freeze-dried” are used herein as synonyms.
  • Compound I is a broad spectrum cephalosporin antibacterial targeted for mammals, in particular, dogs and cats.
  • M + is Na +
  • the preparation of Compound I wherein M + is Na + (hereinafter the "sodium salt") is described in U.S. Patent Nos. 6,001 ,997, 6,020,329, 6077,952, as well as EP1178049A1; incorporated herein by reference in their entirety.
  • the K + and Li + salts of Compound I may be prepared by one of ordinary skill in the art, as described in the preparation of the sodium salt of compound I, but substituting an appropriate K* or Li + salt.
  • the antibiotic compounds of the present invention are active against a wide range of organisms, including both Gram-negative organisms (e.g.
  • Compound I can be used to treat, inter alia, bacterial infections of the skin, soft tissue and urinary tract.
  • conditions or infections caused by or complicated by Gram positive and/or Gram negative bacteria are: canine pneumonia, feline pneumonia, canine pyoderma, feline pyoderma, pasteurellosis, pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis associated with infection by Staphylococcus spp.
  • Staphylococcus intermedius Staphyloccus aureus
  • Escherichia coli Streptococcus spp.
  • Beta Hemolytic Streptococcus spp. Pasteurella multocida
  • Bacteriodes spp. Fusobacterium spp., Porphyromonas spp., Prevotella spp., Peptostreptococcus spp.
  • Clostridium spp. uncomplicated skin and soft tissue infections, abscesses, osteomyelitis, and puerperal fever associated with infection by Staphylococcus aureus, S. intermedius, coagulase-positive staphylococci, S.
  • epidermidis S. hemolyticus, Streptococcus ssp, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, uncomplicated acute urinary tract infections associated with infection by Staphylococcus ssp or E. coli.; odontogenic infection associated with infection by viridans streptococci; urinary tract infection in dogs and cats associated with infection by E. coli; skin and soft tissue infections in dogs and cats associated with infection by Staph. epidermidis, Staph. intermedius, coagulase neg. Staph. or P.
  • multocida infections of the oral cavity in dogs and cats associated with infection by Alcaligenes spp., Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium, Peptostreptococcus, Porphyromonas, or Prevotella.
  • cephalosporin derivatives including compounds of Formula I, were disclosed in International Patent Application publication number WO 92/01696 and by Bateson etal in The Journal of Antibiotics, Feb.1994, vol.47, no.2, at pages 253-256. Various mouse data are also disclosed in the latter paper. Both of these publications are herein incorporated in their entirety.
  • a male dog was dosed intravenously with an aqueous solution of Compound I.
  • Blood plasma was sampled at times up to 28 days post dosing. Plasma samples were extracted and assayed to determine the concentration by both bioassay and HPLC as follows: 1 mL of plasma (or standards of spiked dog plasma) were acidified to a pH of less than 3 with hydrochloric acid, then shaken with 26 mL of ethyl acetate. The layers were separated by centrifugation. 22 mL of the organic layer was transferred into a fresh container and 2.0 mL of 0.1 M phosphate buffer, pH 7.0, was added. After shaking and centrifugation, the aqueous phase was recovered and assayed.
  • samples were assayed by hole-in-the-plate microbiological bioassay on large plates (200 mL Mueller Hinton agar) seeded with M. luteus. Samples were also assayed by HPLC ( ⁇ Bondapk -C18 column eluted with acetonitrile- 0.05M sodium acetate pH 5.0, 15:85, with UV detection at 256nm). Good agreement was obtained between the two assay methods, and the half-life was calculated from bioassay results using standard pharmacokinetic methods.
  • Plasma samples and appropriate standards (1 mL) were first acidified to a pH less than 3.0 with hydrochloric acid then shaken with 30 mL ethyl acetate. The layers were separated by centrifugation then 25mL of the organic layer was removed.2mL of 0.1 M phosphate buffer pH 7.0 was added to the ethyl acetate and shaken to effect a back extraction. After separation of the layers, the aqueous phase was removed and used for the assays.
  • Dried samples were reconstituted in 0.100 mL of mobile phase (15/85 v/v acetonitrile/10 mM HCO 2 NH 4 , pH 3.0), vortexed for 1 minute, centrifuged at 3,000 rpm for 2 minutes, and transferred to an autosampler vial. Single replicates of plasma were analyzed by LC-MS/MS for concentration of compound. Sample analysis was performed on a SCIEX API 365 or 3000 HPLC/MS/MS system. The column effluent was connected to a Turbo-ionspray source set at 4500 V. The collision gas was set to a value of 3. Positive ions were generated in the source and sampled through an orifice into the quadrupple mass filter.
  • the mass spectrometer was adjusted to monitor the precursor and product ions as follows: m/z 454.0 -> m/z 241.0. Half-life was calculated using pharmacokinetic program WINNONLIN v2.1 and determined to be 8.39 +/- 0.97 days.
  • formulations are prepared by dissolving a therapeutically effective amount of the sodium salt of Compound I in an aqueous pharmaceutically acceptable diluent and adjusting the pH, if necessary, to within the range of about 5.0 to about 8.0.
  • the free acid form of Compound I i.e. the carboxylate, instead of the salt
  • a suspension or solution of the free acid may be titrated with, for example, sodium hydroxide, forming the sodium salt of Compound I. Adjustments to pH may be conducted as described above.
  • Aliquots of the resulting solution are clarified and sterile filtered and aseptically transferred to containers appropriate for lyophilization, (e.g. vials), and partially stoppered with lyo-stoppers.
  • the formulation is cooled to freezing, subjected to lyophilization in a manner conventional per se in the art and hermetically capped, forming a stable, dry lyophile formulation.
  • the composition has a low residual water content, less than 1 % by weight, based on the weight of the lyophile. In a more preferred embodiment, the composition has a residual water content level of less than 0.5% by weight.
  • a "therapeutically effective amount" for a dosage unit may typically about 50 to about 500 mg of active ingredient. (US 6020,329; Col 16, line 3).
  • the dose may vary, however, depending on the species, variety, etc. of animal to be treated, the severity and type of infection and the body weight of the animal. Accordingly, based upon body weight, typical dose ranges of the active ingredient may be from about 0.01 to about 100 mg per kg of body weight of the animal. Preferably, the range is from about 1 to about 20 mg per kg of body weight, and more preferably, from about 4 to about 12 mg per kg of body weight.
  • Compounds of Formula I may be administered either alone or in combination with one or more agents used in the treatment or prophylaxis of disease or in the reduction or suppression of symptoms.
  • agents which are provided by way of illustration and should not be construed as limiting
  • antiparasitics eg arylpyrazoles such as fipronil, lufenuron, imidacloprid, avermectins (eg abamectin, ivermectin, doramectin, selamectin), milbemycins, organophosphates, pyrethroids; antihistamines, eg chlorpheniramine, trimeprazine, diphenhydramine, doxylamine; antifungals, eg fluconazole, ketoconazole, itraconazole, griseofulvin, amphotericin B; antibacterials, eg enroflaxacin, marbofloxacin, ampicillin, am
  • composition of the formulations may optionally contain auxiliary ingredients, as known in the art, such as buffers, bulking agents, diluents, co- solvents, solvents, preservatives, chelating agents, antioxidants, tonicity adjusters, whose presence may help to provide a rapidly soluble freeze-dried product or extend the storage time of the formulation.
  • auxiliary ingredients such as buffers, bulking agents, diluents, co- solvents, solvents, preservatives, chelating agents, antioxidants, tonicity adjusters, whose presence may help to provide a rapidly soluble freeze-dried product or extend the storage time of the formulation.
  • an example of a possible solvent and co-solvent is ethanol.
  • An example of a chelating agent is ethylenediaminetetraacetic acid.
  • An example of an antioxidant is ascorbic acid.
  • An example of a tonicity adjuster is dextrose.
  • the compound of Formula I may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a ⁇ -lactamase inhibitor may be employed. (US 6,020,329; Col 16, lines 15-18)
  • formulations of Compound I with or without various buffers have a relatively narrow range of stability between a pH of about 5.0 to about 8.0.
  • optimal solution and solid state stability are achieved at a pH of about 6.0 to about 7.5. Adjustment of pH may be accomplished by either titrating to the desired pH range with, for example, a 10% solution of sodium hydroxide or hydrochloric acid, or using an appropriate buffer.
  • Typical buffers include phosphate, acetate, citrate, carbonate, and glycine. In a preferred embodiment, phosphate is used as a buffer. In a more preferred embodiment, citrate is used as a buffer.
  • the water-soluble bulking agent suitable for use in the present invention can be any of the pharmaceutically acceptable inert solid materials typically used for lyophilization.
  • Bulking agents may improve stability and/or provide a more rapidly soluble freeze-dried product.
  • Such bulking agents include, for example, sugars such as glucose, maltose, sucrose and lactose; polyalcohols such as sorbitol and mannitol; amino acids such as glycine; polymers such as polyvinylpyrrolidone; polysaccharides such as dextran; certain inorganic salts such as sodium or potassium phosphates, or sodium chloride.
  • the ratio of the weight of the bulking agent to the weight of Compound I used in the compositions of the present invention should generally be within the range of from about 0.01 to about 100, depending upon the bulking agent utilized.
  • polyhydroxy compounds are the bulking agent of choice.
  • sucrose is the bulking agent and was found to stabilize the sodium salt of Compound I when co-lyophilized therewith.
  • sucrose/Compound I ratio The optimum ratio of sucrose/Compound I, however, was unpredictable, absent experimentation. For example, it was determined that, compared to formulations without sucrose additions, a relatively small amount of sucrose (e.g. sucrose/sodium salt of Compound I ratio of 0.4) increased the extent of degradation of the sodium salt of Compound I. On the other hand, a sucrose/sodium salt of Compound I ratio of 1 exhibited similar stability as formulations wherein no sucrose was added. Ratios greater than 1.0, however, increased the stability of formulations of the sodium salt of Compound I. In a preferred embodiment, the sucrose/sodium salt of Compound I ratio ranges from greater than 1.0 to about 10.
  • the sucrose/sodium salt of Compound I ratio is about 3. Higher sucrose/Compound ratios may be utilized. A high sucrose concentration is limited, however, by practical considerations of viscosity of high concentrated solution, impacting syringibility of the reconstituted solution. Furthermore, high sucrose concentrations may create injection site intolerance for injectable preparations. As a general rule, viscosity of 25-30 mPa «s (millipascals • second), wherein "-" is defined as “multiplied by”, can be considered as an upper limit for injectable preparations in the pharmaceutical industry. This translates to an approximate maximum 60% sucrose solution at 40°C. (M.Mathlouthi, J.
  • the level of efficacy obtained varies according to the chemical structure of the preservative, its concentration and the physical and chemical characteristics of the medicinal product (especially pH).
  • the design of the pack and the temperature at which the product is stored will also affect the level of activity of any antimicrobial preservatives present.
  • Useful preservatives may include m-benzoic acid and its salts, sorbic acid and its salts, alkyl esters of parahydroxybenzoic acid, phenol, chlorobutanol, benzyl alcohol, thimerosal, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, m-cresol and chlorocresol. Mixtures of the aforementioned preservatives may also be employed.
  • formulations of Compound I containing antimicrobial preservatives were effective in satisfying United States Pharmacopeia (hereinafter "USP") criteria for antimicrobial effectiveness.
  • USP United States Pharmacopeia
  • various formulations of the following preservatives were found to satisfy USP criteria, for example, methyl paraben, propylparaben, m-cresol and benyzl alcohol.
  • EP European Pharmacopeia
  • other preservatives were more appropriate (e.g. benzethonium chloride and combinations of several preservatives such as methylparaben, propylparaben and benzyl alcohol, in one combination, and methyl paraben and m-cresol in another combination.
  • Formulations of Compound I can be isolated by drying, preferably by lyophilization as known in the art.
  • the lyophile formulations are produced with ampule lyophilization, vial lyophilization, tray lyophilization, or like conventional methods by cooling the formulations at subzero temperature to freezing.
  • the frozen material is then dried under vacuum by subliming the water component originally contained in the solution as a solvent, thus leaving a solid lyophilized cake.
  • the excipients described above, Compound I, or the pharmaceutically acceptable salt of Compound I are successively dissolved under stirring in a suitable amount of water for injections. Then, further water is added to reach the desired final volume.
  • the resulting solution is clarified, sterile filtered and aseptically distributed in sterile containers (e.g. vials) of desired capacity. Freeze- drying the solution is then performed and the vials are hermetically sealed according to conventional procedures.
  • the lyophilized drug product is amorphous Compound I, and more preferably the sodium salt thereof.
  • a product solution can be reconstituted by dissolving the dry formulation in water for injection, bacteriostatic water for injection or another pharmaceutically acceptable diluent (e.g. isotonic solution of sodium chloride, water for injection with ethanol or citrate buffer, and bacteriostatic water for injection with benzyl alcohol) in an amount sufficient to generate a solution of the required strength for parenteral administration to patients.
  • bacteriostatic water for injection or another pharmaceutically acceptable diluent e.g. isotonic solution of sodium chloride, water for injection with ethanol or citrate buffer, and bacteriostatic water for injection with benzyl alcohol
  • An amount of Compound I may be administered such that the composition provides the desired therapeutical effect as disclosed in U.S. Patent Nos. 6,001 ,997, 6,020,329 and 6,077,952.
  • the injectable reconstituted solutions of the invention may be administered, according to a variety of possible dose schedules.
  • the sodium salt of Compound I was formulated into lyophilized injectable preparations and stability of the formulations was measured.
  • the examples below are intended to illustrate particular embodiments of the invention and are not intended to limit the specification, including the claims, in any manner.
  • compositions described in Tables 3-6 demonstrate the increased instability of compositions, both buffered and unbuffered, outside the pH range of about 5.0 to about 8.0.
  • sodium salt of Compound I was dissolved in either deionized water or in citrate buffer solutions at 50 mg/mL.
  • solution pH was adjusted with a 10% solution of hydrochloric acid after dissolution of the sodium salt of Compound I (TABLE 3).
  • a buffered solution was prepared with citrate and adjusted with a 10% sodium hydroxide solution, upon which the sodium salt of Compound I was dissolved therein (TABLE 4).
  • FTS Kinetics freeze dryer FTS Systems, Stone Ridge, New York.
  • compositions were frozen using a two-step freezing protocol (at -25 Q C and -40 e C), followed by primary drying at -27 e C for approximately 22 hours, followed by a secondary drying with increased steps of temperature to 0 S C, 25 Q C and 50 ⁇ C.
  • the pressure during primary and secondary drying was set at 60 millitorr.
  • formulations 4 and 5 had an acceptable long-term stability, (i.e. degradation after 18 months at 25 9 C is less than 10%).
  • Formulations with a pH less than or equal to 4.1 demonstrated degradation at greater than 10%, which is typically unacceptable in the pharmaceutical industry for pharmaceutical products.
  • the optimal stability for formulations utilizing a citrate buffer was between pH of about 6.0 to about 7.0.
  • Example 3 Formulation with pH Adjusted by Citrate Buffer 0.6 grams of the sodium salt of Compound I were dissolved in 12 mL of
  • AET' Antimicrobial Effectiveness Tests
  • EP European Pharmacopoeia
  • USP United States Pharmacopeia
  • AET were conducted on a solution containing the sodium salt of Compound I (80 mg/mL) and methylparaben (1.8 mg/mL) in 20 mM citrate buffer. The results of AET are provided in Table 9.
  • the formulation satisfied USP criteria (see Table 12 for acceptance criteria) for all microorganisms. Furthermore, the formulation satisfied criteria A for all microorganisms, except for S. aureus at 6 and 24 hours time points.
  • AET according to EP and USP Procedures, were conducted on a solution containing the sodium salt of Compound I (80 mg/mL), methylparaben (1.8 mg/mL) and propylparaben (0.2 mg/mL) in 20 mM citrate buffer.
  • the results of AET are provided in Table 8.
  • the formulation satisfied USP criteria (see Table 14 for acceptance criteria) for all microorganisms.
  • the formulation satisfied EP criteria A for all microorganisms, except for S. aureus at 6 and 24 hours time points.
  • Example 7 AET of the sodium salt of Compound I and m-cresol (3 mq/ml).
  • AET performed according to EP and USP Procedures, were conducted on a solution of the sodium salt of Compound I (80 mg/mL) and m-cresol (3 mg/mL) prepared by reconstitution of a lyophilized cake of the sodium salt of Compound I with Bacteriostatic Water containing 3mg/mL m-cresol.
  • the results of AET are provided in Table 11.
  • the formulation satisfied USP criteria (see Table 14 for acceptance criteria) for all microorganisms.
  • the formulation satisfied EP criteria A for all microorganisms, except for S. aureus at 6 hours time point.
  • AET performed according to EP and USP Procedures, were conducted on a solution of the sodium salt of Compound I (80 mg/mL), methylparaben (1.8 mg/mL), propylparaben (0.2 mg/mL) and benzyl alcohol (8.6 mg/mL) and 20mM of citrate buffer, prepared by reconstitution of a lyophilized cake of the sodium salt of Compound I, methylparaben and propylparaben with bacteriostatic water for injection containing at least 9 mg/mL benyzl alcohol. Methylparaben and propylparaben were included in the lyophilized cake whereas benzyl alcohol was added with bacteriostatic water for injection.
  • Table 12 The results of AET are provided in Table 12.
  • the formulation satisfied USP criteria (see Table 14 for acceptance criteria) for all microorganisms.
  • EP criteria A for all microorganisms.
  • Example 9 AEP of the sodium salt of Compound I. m-cresol and methylparaben.
  • AET performed according to EP Procedure, were conducted on a solution of the sodium salt of Compound I (80 mg/mL), methylparaben (1.8 mg/mL) and m- cresol (3 mg/mL), prepared by reconstitution of a lyophilized cake of the sodium salt of Compound I with bacteriostatic water for injection containing methylparaben and m-cresol.
  • the results of AET are provided in Table 13.
  • the formulation satisfied EP Criteria A (see Table 14 for acceptance criteria) for S. auereus. TABLE 13. Log reduction of microbial concentration. Formulation of the sodium salt of Compound I, m-cresol and methylparaben.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulations containing an antibacterial alkali metal salt of a cephalosporin compound and methods of treating or preventing bacterial infections in dogs and cats.

Description

FORMULATIONS COMPRISING A CEPHALOSPORIN COMPOUND AND THEIR USE TREATING BACTERIAL INFECTIONS IN CATS AND DOGS
FIELD OF INVENTION
This invention relates to stable lyophilized formulations containing an antibacterial alkali metal salt of a cephalosporin compound, Compound I, wherein M+ is a cation, Na+, K+ or Li+ (hereinafter "Compound I"). In particular, the invention relates to stable lyophilized formulations of Compound I, wherein M+ is Na+, {6R,7R)-7- t[(2Z)-(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-8-oxo-3-[(2S)-tetrahydro-2- furanyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt. The invention also relates to aqueous formulations of Compound I.
Figure imgf000002_0001
M+
The invention is also directed to methods for treating bacterial infections in dogs and cats by administering a compound of Formula I.
BACKGROUND OF THE INVENTION Cephalosporins are widely used and therapeutically important antibiotics.
The compounds of Formula I are broad spectrum cephalosporin antibacterials and are, therefore, useful in the treatment of bacterial infections in animals. (US 6,020,329, Col. 1 , lines 13-14). In particular, Compound I is targeted for dogs and cats with indications for treatment of bacterial infections of the skin, soft tissue, periodontal and urinary tract.
Compound I, wherein M is Na+, and the preparation thereof, are disclosed in U.S. Patent Nos. 6,001 ,997, 6,020,329 and 6,077,952. The text of the aforementioned patents and all other references cited in this specification are hereby incorporated by reference in their entirety. Cephalosporin formulations are generally, however, unstable and a variety of different methods exist to increase stability including, inter alia, the adjustment of pH, crystallization, lyophilization, and the addition of stabilizers, such as sugars.
Cephalosporins may be somewhat stabilized within a certain pH range. The optimum pH range varies widely and is unpredictable for different classes of cephalosporins, requiring experimentation and stability tests. For example, Nassar et al., U.S. Pat. No. 5,401 ,842, disclosed formulations of crystalline cefepime salt buffered with trisodium orthophosphate, sodium bicarbonate, sodium citrate, N- methyl-glucamine and L(+) arginine to a pH of 3.5 to 7.0. K.A. Conners et al. disclose that cephalothin has a broad stability range from a pH of between 2 to 8. Cepharadine, however, stabilizes at a more acidic pH between 1 to 5. Stability for Cefotaxime is achieved in the pH range of 3 to 7. (K.A. Connors, et al. Chemical Stability of Pharmaceuticals, John Wiley & Sons, New York, 1986, p305). In some cases, cephalosporin formulations were stabilized by crystallization and lyophilization. For example, Gotschi, U.S. Pat. No. 5,138,066, describes formulations for parenteral administration as lyophilizates or dry powders for dilution with pharmaceutical carriers such as water or isotonic saline.
Bornstein et al, U.S. Pat. No. 4,002,748, disclose methods of preparing essentially amorphous cefazolin by utilizing certain lyophilization techniques, while Daugherty, EP 0327364, describes a lyophilization method to prepare formulations of a crystalline solvate of a 1-carbacephalosporin.
Some cephalosporins may be stabilized by addition of a variety of different sugars. Whether a certain sugar will stabilize a particular cephalosporin, however, is unpredictable. Furthermore, the ratio of sugar to cephalosporin to achieve optimum stability is also unpredictable. For example, Shamblin et al. disclose that the stability of amorphous cefoxitin sodium was improved by a factor of two when co-lyophilized with sucrose. The stability of cefoxitin was not affected, however, when co-lyophilized with trehalose. S.L. Shamblin, B.C. Hancock, M.J.Pikal, The Chemical Stability of Amorphous Cefoxitin Sodium in the Presence of Glassy Stabilizers, AAPS Pharm. Sci. Vol. I, Issue 4, 1999.
Similarly, Shima et al., EP 0134568B1 , disclose that sugar (glucose, fructose or maltose) or an alkali metal salt of a mineral acid or carboxylic acid stabilized a specific lyophilized cephalosporin at a 0.01 :1 to 0.5:1 weight ratio of stabilizeπcephalosporin. Mannitol, however, was not effective in stabilizing the disclosed cephalosporin compound.
Likewise, Almarsson et al., Tetrahedron 56 (2000) 6877-6885, disclose that sucrose improved chemical stability of a defa-lactam compound at a sucrose/drug ratio of 0.1 :1 to 0.5:1.
Yoshioka, Y. et al., Pharm, Res. 17 (2000), 925-929, disclose the stability of cephalothin in the presence of dextran at a dextran/cephalothin ratio of 200:1.
Conversely, Hirai et al., U.S. Patent No. 4,418,058, disclose that an excess amount, greater than 1 :1 , of a variety of different sugars or sugar alcohols adversely affected chemical stability of cephalosporins. Good stabilizing results were obtained, however, when the amount of added sugar or sugar alcohol was 0.1 to 1 sugar/cephalosporin.
Consequently, one of ordinary skill in the art cannot, in general, predict whether the addition of a particular sugar to any particular cephalosporin will achieve stability. Moreover, the optimum ratio of sugar:cephalosporin is also highly variable and unpredictable, absent experimentation. Furthermore, as discussed above, the optimum pH range of stability for a particular cephalosporin is also unpredictable. A method of administration for Compound I is by parenteral administration.
Other modes of administration include oral and topical. (US 6,020,329, Col. 15, lines 1-2 Compound I is unstable, as both a solid and an aqueous solution. Furthermore, Compound I is hygroscopic. Consequently, a formulation and method for stabilizing Compound I would be a useful addition to the art.
SUMMARY OF THE INVENTION
In a first aspect, the invention provides a pharmaceutical composition comprising a compound of Formula I,
Figure imgf000005_0001
M+ wherein M+ is Na+, K+ or Li+, and an aqueous diluent, wherein the composition has a pH in the range of 5.0 to 8.0.
In a preferred embodiment, the compound of Formula I is amorphous (6f?,7 ?j-7-[[(22)-(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-8-oxo-3-[(2S)- tetrahydro-2-furanyl]-5-thia-1-azabicyclo[4.2.b]oct-2-ene-2-carboxylic acid, monosodium salt.
In a preferred embodiment, M+ is Na+ and the pH is 6.0 to 7.5.
In a preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable buffer.
In a more preferred embodiment, the buffer is carbonate, phosphate, citrate or acetate, and the pH within a range of 6.0 to 7.5.
In a preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable bulking agent.
In a more preferred embodiment, the bulking agent is selected from sugars, polyalcohols, amino acids, polymers, polysaccharides or inorganic salts. In a preferred embodiment, the sugars are selected from glucose, maltose, sucrose and lactose; the polyalcohols are sorbitol or mannitol; the amino acid is glycine; the polymer is polyvinylpyrrolidone; the polysaccharide is dextran; and the inorganic salts are sodium or potassium phosphates or sodium chloride. In a preferred embodiment, the composition has a bulking agent/compound of Formula I ratio greater than 1.0, but less than 100.
In a more preferred embodiment, the ratio is greater than 1 , but less than
10.
In a morr preferred embodiment, the bulking agent is sucrose and the composition has a sucrose/compound of Formula I ratio of 3.
In another aspect, the invention is directed to a pharmaceutical composition comprising a compound of Formula I,
Figure imgf000006_0001
wherein M+ is Na+, K+ or Li+, an aqueous diluent and a pharmaceutically acceptable bulking agent.
In a preferred embodiment, the bulking agent is selected from sugars, polyalcohols, amino acids, polymers, polysaccharides or inorganic salts.
In a more preferred embodiment, the sugar is selected from glucose, maltose, sucrose or lactose; the polyalcohols are sorbitol or mannitol; the amino acid is glycine; the polymer is polyvinylpyrrolidone; the polysaccharide is dextran; and the inorganic salts are sodium or potassium phosphates or sodium chloride.
In another embodiment, the composition has a bulking agent/compound of Formula I ratio of greater than 1 , but less than 10. In a preferred embodiment, M+ is Na+ and the bulking agent is sucrose, wherein the composition has a sucrose/compound of Formula I ratio of 3.
In a preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable buffer. In a preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable preservative.
In a more preferred embodiment, the preservative is methylparaben, propylparaben, m-cresol, benzalkonium chloride, benzethonium chloride or benzyl alcohol, or a combination of two or more thereof.
In a more preferred embodiment, the preservative is a combination of either (a) methylparaben, propylparaben and benzyl alcohol; or (b) methylparaben and m- cresol.
In another embodiment, the pharmaceutical composition further comprises a citrate buffer.
In another aspect, the invention is directed to a pharmaceutical composition comprising a compound of Formula I,
Figure imgf000007_0001
M+ wherein M+ is Na+, further comprising an optional pharmaceutically acceptable buffer, an optional pharmaceutically acceptable preservative, an optional pharmaceutically acceptable bulking agent and an aqueous diluent, wherein the composition has a pH of 6.0 to 7.5.
In a preferred embodiment, the buffer is citrate; the preservative is methylparaben, propylparaben, m-cresol, benzalkonium chloride, benzethonium chloride or benzyl alcohol or a combination of two or more thereof; and the optional bulking agent is sucrose.
In a preferred embodiment, the pharmaceutical composition comprises a compound of Formula I, prepared by lyophilizing the pharmaceutical composition as described above. In another aspect, the invention is directed to a kit comprising a) A therapeutically effect amount of a lyophilized pharmaceutical composition comprising a compound 1 of Formula I;
Figure imgf000008_0001
M+
b) An aqueous pharmaceutically acceptable diluent; and c) A first and second container means for containing the composition (1) and the diluent (2), wherein the first container is adapted to receive the diluent from the second container.
In another aspect, the invention is directed to a method of treating or preventing a condition caused by a bacterial infection in dogs and cats, comprising administering a therapeutically effective amount of a compound of Formula I
Figure imgf000008_0002
M+ effective in treating such a condition. In another aspect, the invention is directed to a method of treating or preventing a condition caused by a bacterial infection in dogs and cats, comprising administering a therapeutically effective amount of the composition described above. In one embodiment, the condition is a skin, soft tissue or urinary tract bacterial infection.
In another embodiment, the condition or infection is caused by or complicated by Gram positive or Gram negative bacteria. The term "about," as used herein, is defined as a pH of 0.5 above or below the designated upper and lower pH units.
The term "aqueous pharmaceutically acceptable diluent" means water or other pharmaceutically acceptable aqueous solutions containing one or more pharmaceutically acceptable excipients for use in making the compositions of the invention (e.g. isotonic solution of sodium chloride, water for injection with ethanol or phosphate, acetate or citrate buffer, and water for injection with benzyl alcohol).
The term "Na+," as used herein, is defined as a sodium cation.
The term "K+," as used herein, is defined as a potassium cation.
The term "Li+," as used herein, is defined as a lithium cation. The term "composition", as used herein, encompasses, inter alia, (1) solutions comprising Compound I or (2) dry lyophilized residues of such solutions. The solutions may contain one or more optional agents which aid in stabilizing dissolved Compound I and/or that facilitate re-dissolution, upon reconstitution of the lyophile created after lyophilizing solution (1). Such optional agents include, inter alia, bulking agents, preservatives, and buffers, as further disclosed herein.
The term "Compound I" is limited to the pharmaceutically acceptable alkali metal salts of Compound I, wherein M+ is Na+, K+ or Li+, and in particular, includes Compound I, (6 ?,7f? 7-[[(22)-(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-8- oxo-3-[(2S)-tetrahydro-2-furanyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt), wherein M+ is Na+.
The term "lyophilization" means the process of f reeze-drying a composition as known in the art. "Lyophilized" and "freeze-dried" are used herein as synonyms.
The terms "pharmaceutical" and "pharmaceutically" and the like are meant to refer to applications in both human and veterinary fields. DETAILED DESCRIPTION OF THE INVENTION
Compound I is a broad spectrum cephalosporin antibacterial targeted for mammals, in particular, dogs and cats. The preparation of Compound I wherein M+ is Na+ (hereinafter the "sodium salt") is described in U.S. Patent Nos. 6,001 ,997, 6,020,329, 6077,952, as well as EP1178049A1; incorporated herein by reference in their entirety. The K+and Li+ salts of Compound I may be prepared by one of ordinary skill in the art, as described in the preparation of the sodium salt of compound I, but substituting an appropriate K* or Li+ salt. The antibiotic compounds of the present invention are active against a wide range of organisms, including both Gram-negative organisms (e.g. E.coli), and Gram-positive organisms, (e.g.S. aureus). (US 6,020,329, Col 17, lines 28-31). Compound I can be used to treat, inter alia, bacterial infections of the skin, soft tissue and urinary tract. For example, conditions or infections caused by or complicated by Gram positive and/or Gram negative bacteria are: canine pneumonia, feline pneumonia, canine pyoderma, feline pyoderma, pasteurellosis, pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis associated with infection by Staphylococcus spp. (Staphylococcus intermedius, Staphyloccus aureus), Escherichia coli, Streptococcus spp. (Beta Hemolytic Streptococcus spp.), Pasteurella multocida, Bacteriodes spp., Fusobacterium spp., Porphyromonas spp., Prevotella spp., Peptostreptococcus spp., and Clostridium spp., uncomplicated skin and soft tissue infections, abscesses, osteomyelitis, and puerperal fever associated with infection by Staphylococcus aureus, S. intermedius, coagulase-positive staphylococci, S. epidermidis, S. hemolyticus, Streptococcus ssp, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, uncomplicated acute urinary tract infections associated with infection by Staphylococcus ssp or E. coli.; odontogenic infection associated with infection by viridans streptococci; urinary tract infection in dogs and cats associated with infection by E. coli; skin and soft tissue infections in dogs and cats associated with infection by Staph. epidermidis, Staph. intermedius, coagulase neg. Staph. or P. multocida; infections of the oral cavity in dogs and cats associated with infection by Alcaligenes spp., Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium, Peptostreptococcus, Porphyromonas, or Prevotella.
It was determined that the compounds of Formula I, as well as similar compounds disclosed in U.S. Patent Nos. 6,001 ,997, 6,020,329 and 6,077,952, exhibit an unexpectedly long half-life in dogs and cats, especially in view of comparable antibiotics. For example, Table I lists well-known antibiotics and their respective half-lives in different mammals, such as in mice, rats, dogs and cats. TABLE I: Half-life of Known Antibiotics
Figure imgf000011_0002
(Cefpodoxime data from "Abstracts of the 1996 ICAAC"; Abstract 593. All other data compiled from: "CRC Handbook of Comparative Pharmacokinetics and Residues of Veterinary Antimicrobials", J. Edmond Riviere; Arthur L. Craigmill, Stephen F. Sundlof CRC Press 1991; Routes of administration: "IV" - intravenous; "IM" = intramuscular; "PO" = per os; "SC" = subcutaneous)
A number of cephalosporin derivatives, including compounds of Formula I, were disclosed in International Patent Application publication number WO 92/01696 and by Bateson etal in The Journal of Antibiotics, Feb.1994, vol.47, no.2, at pages 253-256. Various mouse data are also disclosed in the latter paper. Both of these publications are herein incorporated in their entirety.
In particular, following administration of the compound of Formula II, the half- life in the mouse and rat were determined to be 2.2 and 3.9 hours, after per os administration, respectively. Unexpectedly, however, in dogs and cats the half-life was in both cases dramatically increased, as is demonstrated below in Table II.
Figure imgf000011_0001
TABLE 2: Half-life in Dogs and Cats
Figure imgf000012_0001
Note [1] Dose expressed as corresponding free acid : i.e. M+= H. Concentrations measured w.r.t. free acid.
EXPERIMENTAL DETAILS
a. Pharmacokinetics
Experiment 1 : Intravenous Dog
A male dog was dosed intravenously with an aqueous solution of Compound I. Blood plasma was sampled at times up to 28 days post dosing. Plasma samples were extracted and assayed to determine the concentration by both bioassay and HPLC as follows: 1 mL of plasma (or standards of spiked dog plasma) were acidified to a pH of less than 3 with hydrochloric acid, then shaken with 26 mL of ethyl acetate. The layers were separated by centrifugation. 22 mL of the organic layer was transferred into a fresh container and 2.0 mL of 0.1 M phosphate buffer, pH 7.0, was added. After shaking and centrifugation, the aqueous phase was recovered and assayed. Following processing, samples (and standards) were assayed by hole-in-the-plate microbiological bioassay on large plates (200 mL Mueller Hinton agar) seeded with M. luteus. Samples were also assayed by HPLC (μBondapk -C18 column eluted with acetonitrile- 0.05M sodium acetate pH 5.0, 15:85, with UV detection at 256nm). Good agreement was obtained between the two assay methods, and the half-life was calculated from bioassay results using standard pharmacokinetic methods.
Experiment 2: Subcutaneous Dog Two dogs were dosed with compound of Formula I by subcutaneous injection. Blood plasma was sampled at times up to 28 days post-dosing. Plasma samples and appropriate standards were prepared by deproteination by the addition of an equal volume of acetonitrile and centrifugation (3000 r.p.m. for 10 min.). Supernatant was assayed by a specific HPLC method to determine the concentration (μBondapk
-C18 column eluted with acetonitrile- 0.05M sodium acetate pH 5.0, 15:85, at 1.0 mL/min with UV detection at 256nm). Pharmacokinetic parameters were calculated using the program PCNONLIN.
Experiment 3: per os Dog
Six dogs were dosed orally with the pivaloyloxymethyl-ester pro-drug, compound of Formula II, and the resulting plasma concentrations were determined by both bioassay and HPLC. Following dosing, blood plasma was sampled up to 696 hours (29 days). Plasma samples and appropriate standards (1 mL) were first acidified to a pH less than 3.0 with hydrochloric acid then shaken with 30 mL ethyl acetate. The layers were separated by centrifugation then 25mL of the organic layer was removed.2mL of 0.1 M phosphate buffer pH 7.0 was added to the ethyl acetate and shaken to effect a back extraction. After separation of the layers, the aqueous phase was removed and used for the assays. Following processing, samples (and standards) were assayed by hole-in-the-plate microbiological bioassay on large plates (200 mL Mueller Hinton agar) seeded with M. luteus. Samples were also assayed by HPLC (μBondapk -C18 column eluted with acetonitrile- 0.05M sodium acetate pH 5.0, 15:85,at 1.5 mL/min with UV detection at 256nm). There was good agreement between the two assay methods (r=0.9716) half-life was calculated from the bioassay data.
Experiment 4: Subcutaneous Cat Four cats were dosed at 8 mg/kg by subcutaneous injection of Compound I. Blood samples were taken at intervals to 35 days post-dosing and the plasma assayed to determine the concentration of the corresponding free acid by HPLC/MS/MS. Plasma samples (100 mL) were aliquotted into centrifuge tubes, then 400 mL of acetonitrile was added. Following vortexing (60 sec.) and centrifugation (20,800 x g for 10 minutes), 0.450 mL of the supernatant was transferred into clean centrifuge tubes, and evaporated to dryness at approximately 50°C under N2. Dried samples were reconstituted in 0.100 mL of mobile phase (15/85 v/v acetonitrile/10 mM HCO2NH4, pH 3.0), vortexed for 1 minute, centrifuged at 3,000 rpm for 2 minutes, and transferred to an autosampler vial. Single replicates of plasma were analyzed by LC-MS/MS for concentration of compound. Sample analysis was performed on a SCIEX API 365 or 3000 HPLC/MS/MS system. The column effluent was connected to a Turbo-ionspray source set at 4500 V. The collision gas was set to a value of 3. Positive ions were generated in the source and sampled through an orifice into the quadrupple mass filter. The mass spectrometer was adjusted to monitor the precursor and product ions as follows: m/z 454.0 -> m/z 241.0. Half-life was calculated using pharmacokinetic program WINNONLIN v2.1 and determined to be 8.39 +/- 0.97 days.
b. Efficacy
In an experimentally induced skin infection model study, five out of six dogs had complete clearance of Staphylococcus intermedius 15 days after a single administration of 8 mg/kg of the Compound I.
In a separate study, following a single administration of 8 mg/kg Compound I to healthy dogs, there was a significant reduction of the populations of pathogenic Staphylococci tor four weeks compared to non-treated control animals.
In an experimentally induced abscess model study in cats, there was a substantial reduction in the numbers of Pasteurella multocida, Clostridium perfringens, and Bacteriodes fragilis bacteria 14 days after a single administration of 8 mg/kg Compound I
The above half-life results, together with the potency of the compounds of Formula I, demonstrates that one administration of an equivalent of ca.4-12 mg/kg of Compound I, (e.g.Na salt of compound of Formula I), given by injection (e.g. intramuscularly, subcutaneously or intravenously), to a cat or dog would advantageously provide an efficacious concentration for 7-21 days. This represents a novel and very convenient treatment regime for veterinary practitioners and cat and dog owners alike. It has been determined, however, that Compound I is unstable both as a solid and a liquid. In evaluating possible formulations, stability experiments were conducted. As used herein, "stable" or "stabilized" means less than or equal to about 10% decomposition of Compound I.
While many cephalosporins may be stabilized by crystallization, it has been determined that Compound I is not particularly amenable to crystallization techniques on a commercial scale. Consequently, Compound I is in an amorphous state and is hygroscopic. It was determined that optimal long-term stability of Compound I is achieved at a low residual water content. Accordingly, lyophilization of formulations of Compound I provide preferred stability. With respect to the present invention, stable formulations of Compound I were developed, overcoming the inherent stability problems previously hampering long-term storage goals. It was determined that Compound I could be stabilized and formulated into injectable preparations by formulating Compound I with an aqueous pharmaceutically acceptable diluent, such that the pH is in the range of about 5.0 to about 8.0.
For example, formulations are prepared by dissolving a therapeutically effective amount of the sodium salt of Compound I in an aqueous pharmaceutically acceptable diluent and adjusting the pH, if necessary, to within the range of about 5.0 to about 8.0. Alternatively, the free acid form of Compound I (i.e. the carboxylate, instead of the salt) may be utilized as starting material. A suspension or solution of the free acid may be titrated with, for example, sodium hydroxide, forming the sodium salt of Compound I. Adjustments to pH may be conducted as described above. Aliquots of the resulting solution, the quantity of which is dependent upon the ultimate desired reconstituted concentration of Compound I, are clarified and sterile filtered and aseptically transferred to containers appropriate for lyophilization, (e.g. vials), and partially stoppered with lyo-stoppers. As described hereinafter, the formulation is cooled to freezing, subjected to lyophilization in a manner conventional per se in the art and hermetically capped, forming a stable, dry lyophile formulation. In a preferred embodiment, the composition has a low residual water content, less than 1 % by weight, based on the weight of the lyophile. In a more preferred embodiment, the composition has a residual water content level of less than 0.5% by weight. As used herein, a "therapeutically effective amount" for a dosage unit may typically about 50 to about 500 mg of active ingredient. (US 6020,329; Col 16, line 3). The dose may vary, however, depending on the species, variety, etc. of animal to be treated, the severity and type of infection and the body weight of the animal. Accordingly, based upon body weight, typical dose ranges of the active ingredient may be from about 0.01 to about 100 mg per kg of body weight of the animal. Preferably, the range is from about 1 to about 20 mg per kg of body weight, and more preferably, from about 4 to about 12 mg per kg of body weight. (PCS10965; p7, Iines7-11 ) The veterinary practitioner, or one skilled in the art, will be able to determine the dosage suitable for the particular individual patient, which may vary with the species, age, weight and response of the particular patient, as well as the bacterial species involved. The above dosages are exemplary of the average case. Accordingly, higher or lower dosage ranges may be warranted, depending upon the above factors, and are within the scope of this invention.
Compounds of Formula I may be administered either alone or in combination with one or more agents used in the treatment or prophylaxis of disease or in the reduction or suppression of symptoms. Examples of such agents (which are provided by way of illustration and should not be construed as limiting) include antiparasitics, eg arylpyrazoles such as fipronil, lufenuron, imidacloprid, avermectins (eg abamectin, ivermectin, doramectin, selamectin), milbemycins, organophosphates, pyrethroids; antihistamines, eg chlorpheniramine, trimeprazine, diphenhydramine, doxylamine; antifungals, eg fluconazole, ketoconazole, itraconazole, griseofulvin, amphotericin B; antibacterials, eg enroflaxacin, marbofloxacin, ampicillin, amoxycillin; anti-inflammatories eg prednisolone, betamethasone, dexamethasone, carprofen, ketoprofen; steroids or other antipruritic agents; dietary supplements, eg gamma- linoleic acid; and emollients. Therefore, the invention further provides for uses, etc., of compounds of formula (I) and one or more selected compounds from the above list as a combined preparation for simultaneous, separate or sequential use in the treatment of diseases or conditions according to the invention.
The composition of the formulations may optionally contain auxiliary ingredients, as known in the art, such as buffers, bulking agents, diluents, co- solvents, solvents, preservatives, chelating agents, antioxidants, tonicity adjusters, whose presence may help to provide a rapidly soluble freeze-dried product or extend the storage time of the formulation.
An example of a possible solvent and co-solvent is ethanol. An example of a chelating agent is ethylenediaminetetraacetic acid. An example of an antioxidant is ascorbic acid. An example of a tonicity adjuster is dextrose. Furthermore, the compound of Formula I may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a β-lactamase inhibitor may be employed. (US 6,020,329; Col 16, lines 15-18)
Unlike most cephalosporins with typical broader pH ranges of stability, it was determined that formulations of Compound I with or without various buffers have a relatively narrow range of stability between a pH of about 5.0 to about 8.0. In particular, and in a preferred embodiment, optimal solution and solid state stability are achieved at a pH of about 6.0 to about 7.5. Adjustment of pH may be accomplished by either titrating to the desired pH range with, for example, a 10% solution of sodium hydroxide or hydrochloric acid, or using an appropriate buffer. Typical buffers include phosphate, acetate, citrate, carbonate, and glycine. In a preferred embodiment, phosphate is used as a buffer. In a more preferred embodiment, citrate is used as a buffer.
The water-soluble bulking agent suitable for use in the present invention can be any of the pharmaceutically acceptable inert solid materials typically used for lyophilization. Bulking agents may improve stability and/or provide a more rapidly soluble freeze-dried product. Such bulking agents include, for example, sugars such as glucose, maltose, sucrose and lactose; polyalcohols such as sorbitol and mannitol; amino acids such as glycine; polymers such as polyvinylpyrrolidone; polysaccharides such as dextran; certain inorganic salts such as sodium or potassium phosphates, or sodium chloride.
The ratio of the weight of the bulking agent to the weight of Compound I used in the compositions of the present invention should generally be within the range of from about 0.01 to about 100, depending upon the bulking agent utilized. In a preferred embodiment, polyhydroxy compounds are the bulking agent of choice. In a more preferred embodiment, sucrose is the bulking agent and was found to stabilize the sodium salt of Compound I when co-lyophilized therewith.
The optimum ratio of sucrose/Compound I, however, was unpredictable, absent experimentation. For example, it was determined that, compared to formulations without sucrose additions, a relatively small amount of sucrose (e.g. sucrose/sodium salt of Compound I ratio of 0.4) increased the extent of degradation of the sodium salt of Compound I. On the other hand, a sucrose/sodium salt of Compound I ratio of 1 exhibited similar stability as formulations wherein no sucrose was added. Ratios greater than 1.0, however, increased the stability of formulations of the sodium salt of Compound I. In a preferred embodiment, the sucrose/sodium salt of Compound I ratio ranges from greater than 1.0 to about 10. In an even more preferred embodiment, the sucrose/sodium salt of Compound I ratio is about 3. Higher sucrose/Compound ratios may be utilized. A high sucrose concentration is limited, however, by practical considerations of viscosity of high concentrated solution, impacting syringibility of the reconstituted solution. Furthermore, high sucrose concentrations may create injection site intolerance for injectable preparations. As a general rule, viscosity of 25-30 mPa«s (millipascals • second), wherein "-" is defined as "multiplied by", can be considered as an upper limit for injectable preparations in the pharmaceutical industry. This translates to an approximate maximum 60% sucrose solution at 40°C. (M.Mathlouthi, J. Genotelle, in: M.Mathlouthi, Sucrose. Properties and Applications, Blackie Academic & Professional, London, 1995, p.137). For example, if the concentration of Compound I in solution is 6% by weight, the acceptable sucrose/Compound I ratio would be 10:1. If Compound I concentration is 3%, the acceptable sucrose/Compound I ratio would be 20:1. These are but two examples of many possible ratios. Antimicrobial preservatives are frequently added to pharmaceutical formulations to prevent microbial contamination. As used herein, the word "preservative" means a compound, or combination of compounds, added to prevent or inhibit the growth of micro-organisms which could present a risk of infection or degradation of the medicinal product. Generally, the level of efficacy obtained varies according to the chemical structure of the preservative, its concentration and the physical and chemical characteristics of the medicinal product (especially pH). The design of the pack and the temperature at which the product is stored will also affect the level of activity of any antimicrobial preservatives present. Useful preservatives may include m-benzoic acid and its salts, sorbic acid and its salts, alkyl esters of parahydroxybenzoic acid, phenol, chlorobutanol, benzyl alcohol, thimerosal, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, m-cresol and chlorocresol. Mixtures of the aforementioned preservatives may also be employed.
In the present invention, formulations of Compound I containing antimicrobial preservatives were effective in satisfying United States Pharmacopeia (hereinafter "USP") criteria for antimicrobial effectiveness. In particular, various formulations of the following preservatives were found to satisfy USP criteria, for example, methyl paraben, propylparaben, m-cresol and benyzl alcohol. To satisfy European Pharmacopeia (hereinafter "EP") criteria for antimicrobial effectiveness, however, other preservatives were more appropriate (e.g. benzethonium chloride and combinations of several preservatives such as methylparaben, propylparaben and benzyl alcohol, in one combination, and methyl paraben and m-cresol in another combination. Formulations of Compound I can be isolated by drying, preferably by lyophilization as known in the art. Usually the lyophile formulations are produced with ampule lyophilization, vial lyophilization, tray lyophilization, or like conventional methods by cooling the formulations at subzero temperature to freezing. The frozen material is then dried under vacuum by subliming the water component originally contained in the solution as a solvent, thus leaving a solid lyophilized cake. Thus, for example, the excipients described above, Compound I, or the pharmaceutically acceptable salt of Compound I, are successively dissolved under stirring in a suitable amount of water for injections. Then, further water is added to reach the desired final volume. The resulting solution is clarified, sterile filtered and aseptically distributed in sterile containers (e.g. vials) of desired capacity. Freeze- drying the solution is then performed and the vials are hermetically sealed according to conventional procedures.
The lyophilized drug product is amorphous Compound I, and more preferably the sodium salt thereof. When a product solution is required, it can be reconstituted by dissolving the dry formulation in water for injection, bacteriostatic water for injection or another pharmaceutically acceptable diluent (e.g. isotonic solution of sodium chloride, water for injection with ethanol or citrate buffer, and bacteriostatic water for injection with benzyl alcohol) in an amount sufficient to generate a solution of the required strength for parenteral administration to patients.
An amount of Compound I may be administered such that the composition provides the desired therapeutical effect as disclosed in U.S. Patent Nos. 6,001 ,997, 6,020,329 and 6,077,952. The injectable reconstituted solutions of the invention may be administered, according to a variety of possible dose schedules. EXAMPLES
To confirm the advantageous effects of the present invention, the sodium salt of Compound I, was formulated into lyophilized injectable preparations and stability of the formulations was measured. The examples below are intended to illustrate particular embodiments of the invention and are not intended to limit the specification, including the claims, in any manner.
A. Stabilization of lyophilized formulations bypH adjustment.
The formulations described in Tables 3-6, demonstrate the increased instability of compositions, both buffered and unbuffered, outside the pH range of about 5.0 to about 8.0. As set forth below in Tables 3 and 4, the sodium salt of Compound I was dissolved in either deionized water or in citrate buffer solutions at 50 mg/mL.
For formulations 1 -5, solution pH was adjusted with a 10% solution of hydrochloric acid after dissolution of the sodium salt of Compound I (TABLE 3). For formulations 6-13, a buffered solution was prepared with citrate and adjusted with a 10% sodium hydroxide solution, upon which the sodium salt of Compound I was dissolved therein (TABLE 4). One mL aliquots of solutions of the sodium salt of Compound I were filled in 10 mL vials, and lyophilized using a FTS Kinetics freeze dryer (FTS Systems, Stone Ridge, New York). During lyophilization, the compositions were frozen using a two-step freezing protocol (at -25QC and -40eC), followed by primary drying at -27eC for approximately 22 hours, followed by a secondary drying with increased steps of temperature to 0SC, 25QC and 50δC. The pressure during primary and secondary drying was set at 60 millitorr.
Examples of the solution preparation procedures are given below.
TABLE 3. Composition of formulations with HCI.
Figure imgf000020_0001
"+" sign means that HCI was added to the formulation whereas "-" sign indicates that HCI was not added. TABLE 4. Composition of formulations with Citric Acid.
Figure imgf000021_0001
*pH of the solutions were adjusted to the specified values with 10% sodium hydroxide solution prior to lyophilization.
The samples were stored at 409C for 12 weeks. The remaining amount of Compound I was then measured by reverse-phase High Pressure Liquid Chromatography ("HPLC"), using a Waters (Milford, MA) HPLC system with an Ultraviolet ("UV") detector set at 256 nm and a Kromasil C4 column (MetaChem
Technologies Inc., Torrance, CA). A gradient method was utilized with mobile phase A consisting of 9:1 ratio v/v 0.025M sodium phosphate buffer solution, pH 6.5: acetonitrile, and mobile phase B consisting of 4:6 ratio v/v 0.025M sodium phosphate buffer solution, pH 6.5: acetonitrile. Degradation results are reported at Tables 5 and 6 as percentage (%) of initial purity of Compound I. Degradation of the formulation after 18 months storage at a controlled room temperature of 25QC (i.e. typical shelf storage conditions) was calculated using the pseudo-zero order model and the Arrhenius equation with an activation energy of 10 kcal/mol (e.g., K.A. Connors, Chemical Kinetics, 1990, VCH Publishers, Inc., New York). At this activation energy, the degradation rate constant at 40QC (k^) is equal to 2.27*k25 (k25 is the degradation rate constant at 259C). A person of ordinary skill in the art would appreciate the reasonableness of this assumption, based on data reported by Pikal et al. tor other amorphous cephalosporin compounds wherein, k40=2.2*k25. (M.J.Pikal, K.M. Dellerman, Stability testing of pharmaceuticals by high-sensitivity isothermal calorimetry at 259C: cephalosporins in the solid and aquesous solution states, Int. J. Pharm. 50 (1989) 233-252). As set forth in Table 5, formulations 4 and 5 (respectively, pH of 5.1 and 6.0, from Table I) had an acceptable long-term stability, (i.e. degradation after 18 months at 259C is less than 10%). Formulations with a pH less than or equal to 4.1 , however, demonstrated degradation at greater than 10%, which is typically unacceptable in the pharmaceutical industry for pharmaceutical products. As demonstrated in Table 4, the optimal stability for formulations utilizing a citrate buffer, however, was between pH of about 6.0 to about 7.0.
TABLE 5. Percent Compound I after 12 weeks storage at 40°C and estimated shelf life at controlled room temperature 259C
Figure imgf000022_0001
Calculated as described in the text
TABLE 6. Percent Compound I after 12 weeks storage at 40°C and estimated shelf life at controlled room temperature 259C
Figure imgf000022_0002
Calculated as described in the text
Examples of solution preparation for the above stability studies of lyophilized formulations are with specific concentrations as follows: Example 1 Formulation without pH Adjustment
1.0453 grams of the sodium salt of Compound I were dissolved in 20.0 mL de-ionized water. One mL aliquots of the resulting solution were transferred to 10-mL vials, partially stoppered with lyo-stoppers, lyophilized and hermetically capped, as described hereinabove.
Example 2 Formulation with pH Adjusted by HCI
0.5085 grams of the sodium salt of Compound I were dissolved in 10.0 mL de-ionized water. The solution was titrated with 0.1 N hydrochloric acid to pH 3.87. One mL aliquots of the resulting solution were transferred to 10-mL vials, partially stoppered with lyo-stoppers, lyophilized and hermetically capped, as described hereinabove.
Example 3 Formulation with pH Adjusted by Citrate Buffer 0.6 grams of the sodium salt of Compound I were dissolved in 12 mL of
0.05M citrate buffer at pH of 6.0. The resulting solution was filtered and 1 mL aliquots were transferred to 10-mL vials, partially stoppered with lyo-stoppers, lyophilized and hermetically capped, as described hereinabove.
B. Stabilization of lyophilized formulation of the sodium salt of Compound I bv
Bulking Agents.
In each experiment, formulations of the sodium salt of Compound I and sucrose, at different sucrose/sodium salt of Compound I ratios (TABLE 7), were lyophilized according to standard industry procedures, as described hereinabove. Formulations 15 to 18 and 19 to 22 were prepared independently for quality control reproducibility purposes. Stability measurements of formulations 19 to 22 were only taken at 12 weeks. TABLE 7. Composition of formulations
Figure imgf000024_0001
The samples were stored at 40QC for up to 12 weeks. The remaining amount of Compound I was measured by reverse-phase HPLC using gradient solvent method, as described above, and reported as percentage (%) of remaining Compound I. The results, as set forth in TABLE 8, demonstrate that additions of sucrose at a ratio of 3:1 (sucrose/sodium salt of Compound I) improved stability. A lower sucrose/sodium salt of Compound I ratio of 2:5 sucrose was less desirable. Stability of formulation with 1 :1 ratio was similar to the formulation without sucrose.
TABLE 8. Percent Compound I after 12 weeks at 40°C
Figure imgf000024_0002
An example of solution preparation for the above stability studies of lyophilized formulations are is follows:
Example 4 Formulation with Sucrose
0.4818 grams of the sodium salt of Compound I and 0.1964 grams of sucrose were dissolved in 10 mL of de-ionized water. The resulted solution was filled in 1-mL aliquots in 10-mL vials, partially stoppered with lyo-stoppers and lyophilized, as described hereinabove. At the end of the lyophilization cycle, the vials were hermetically capped.
C. Preservatives. Generally, preservatives are not required for cephalosporin formulations, including formulations of Compound I. Formulations stored in multi-dose containers versus single dose containers, however, require the addition of preservatives to satisfy antimicrobial effectiveness in vitro. Various formulations prepared in accordance with the working Examples hereinafter were tested for antimicrobial activity in vitro. Antimicrobial Effectiveness Tests (hereinafter "AET') were performed according to European Pharmacopoeia (EP) Procedures (European Pharmacopoeia, 3d edition, Supplement 201 , Council of Europe, Strasbourg) and United States Pharmacopeia (USP) procedures (U.S. Pharmacopeia, and National Formulary USP24 NF19, 2000, United States Pharmacopeia Convention Inc., Rockville, MD). The effectiveness of formulations containing preservatives and the sodium salt of Compound I is demonstrated in the following examples:
Example 5 AET of the sodium salt of Compound I and methylparaben (1.8 mg/mL)
AET were conducted on a solution containing the sodium salt of Compound I (80 mg/mL) and methylparaben (1.8 mg/mL) in 20 mM citrate buffer. The results of AET are provided in Table 9. The formulation satisfied USP criteria (see Table 12 for acceptance criteria) for all microorganisms. Furthermore, the formulation satisfied criteria A for all microorganisms, except for S. aureus at 6 and 24 hours time points.
TABLE 9. Log reduction of microbial concentration. Formulation of the sodium salt of Compound I and Methylparaban
Figure imgf000025_0001
Corresponds to "no recovery" of microorganisms. Example 6.
AET of the sodium salt of Compound I, Methylparaben (1.8 mg/mL) and Propylparaben (0.2 mg/mL).
AET, according to EP and USP Procedures, were conducted on a solution containing the sodium salt of Compound I (80 mg/mL), methylparaben (1.8 mg/mL) and propylparaben (0.2 mg/mL) in 20 mM citrate buffer. The results of AET are provided in Table 8. The formulation satisfied USP criteria (see Table 14 for acceptance criteria) for all microorganisms. Furthermore, the formulation satisfied EP criteria A for all microorganisms, except for S. aureus at 6 and 24 hours time points.
TABLE 10. Log reduction of microbial concentration. Formulation of the sodium salt of Compound 1. Methylparaban and propylparaben.
Figure imgf000026_0001
Example 7. AET of the sodium salt of Compound I and m-cresol (3 mq/ml). AET, performed according to EP and USP Procedures, were conducted on a solution of the sodium salt of Compound I (80 mg/mL) and m-cresol (3 mg/mL) prepared by reconstitution of a lyophilized cake of the sodium salt of Compound I with Bacteriostatic Water containing 3mg/mL m-cresol. The results of AET are provided in Table 11. The formulation satisfied USP criteria (see Table 14 for acceptance criteria) for all microorganisms. Furthermore, the formulation satisfied EP criteria A for all microorganisms, except for S. aureus at 6 hours time point.
TABLE 11. Log reduction of microbial concentration. Formulation of the sodium salt of Compound I and m-cresol.
Figure imgf000026_0002
Corresponds to "no recovery" of microorganisms Example 8
AET of the sodium salt of Compound I, methylparaben. propylparaben and benzyl alcohol.
AET, performed according to EP and USP Procedures, were conducted on a solution of the sodium salt of Compound I (80 mg/mL), methylparaben (1.8 mg/mL), propylparaben (0.2 mg/mL) and benzyl alcohol (8.6 mg/mL) and 20mM of citrate buffer, prepared by reconstitution of a lyophilized cake of the sodium salt of Compound I, methylparaben and propylparaben with bacteriostatic water for injection containing at least 9 mg/mL benyzl alcohol. Methylparaben and propylparaben were included in the lyophilized cake whereas benzyl alcohol was added with bacteriostatic water for injection. The results of AET are provided in Table 12. The formulation satisfied USP criteria (see Table 14 for acceptance criteria) for all microorganisms. Furthermore, the formulation satisfied EP criteria A for all microorganisms.
TABLE 12. Log reduction of microbial concentration.
Formulation of the sodium salt of Compound I, methylparaben. propylparaben and benzyl alcohol.
Figure imgf000027_0001
Example 9 AEP of the sodium salt of Compound I. m-cresol and methylparaben.
AET, performed according to EP Procedure, were conducted on a solution of the sodium salt of Compound I (80 mg/mL), methylparaben (1.8 mg/mL) and m- cresol (3 mg/mL), prepared by reconstitution of a lyophilized cake of the sodium salt of Compound I with bacteriostatic water for injection containing methylparaben and m-cresol. The results of AET are provided in Table 13. The formulation satisfied EP Criteria A (see Table 14 for acceptance criteria) for S. auereus. TABLE 13. Log reduction of microbial concentration. Formulation of the sodium salt of Compound I, m-cresol and methylparaben.
Figure imgf000028_0001
TABLE 14. AET Acceptance Criteria (USP and EP)
Figure imgf000028_0002
NR = no recovery; Nl = no increase European Pharmacopoeia, 3d edition, Supplement 2001 , Council of Europe,
Strasbourg; U.S. Pharmacopeia, and National Formulary USP24 NF19, 2000, United State Pharmacopeial Convention Inc., Rockville, MD.

Claims

CLAIMS 1. A pharmaceutical composition comprising a compound of Formula I,
Figure imgf000029_0001
M+
wherein M+ is Na+, K+ or Li+, and an aqueous diluent, wherein the composition has a pH in the range of 5.0 to 8.0.
2. A pharmaceutical composition according to Claim 1 , wherein M+ is Na+ and the pH is 6.0 to 7.5.
3. A pharmaceutical composition according to Claims 1 or 2 further comprising an optional pharmaceutically acceptable buffer, an optional pharmaceutically acceptable preservative, an optional pharmaceutically acceptable bulking agent and an aqueous diluent.
4. A pharmaceutical composition comprising a compound of Formula I,
Figure imgf000029_0002
M+
wherein M+ is Na+, K+ or Li+, an aqueous diluent and a pharmaceutically acceptable bulking agent and the composition has a bulking agent/compound of Formula I ratio greater than 1.0, but less than 100.
5. A pharmaceutical composition according to any of the preceding Claims, wherein the composition has a bulking agent/compound of Formula I ratio greater than 1 , but less than 10.
6. A pharmaceutical composition according to Claim 5, wherein the bulking agent is sucrose and the composition has a sucrose/compound of Formula I ratio of 3.
7. A pharmaceutical composition according to Claims 4, 5 or 6 further comprising an optional pharmaceutically acceptable buffer, an optional pharmaceutically acceptable preservative and an aqueous diluent.
8. A pharmaceutical composition according to any of the preceeding
Claims, wherein the preservative is methylparaben, propylparaben, m-cresol, benzalkonium chloride, benzethonium chloride or benzyl alcohol, or a combination of two or more thereof.
9. A pharmaceutical composition according to Claim 8, wherein the preservative is a combination of either (a) methylparaben, propylparaben and benzyl alcohol; or (b) methylparaben and m-cresol.
10. A pharmaceutical composition comprising a compound of Formula I, prepared by lyophilizing the pharmaceutical composition of any of the preceding Claims.
11. A method of treating or preventing a condition caused by a bacterial infection in dogs and cats comprising administering to the dog or cat a therapeutically effective amount of a compound of Formula I
Figure imgf000030_0001
M+ wherein M+ is Na+, K+ or Li+, effective in treating or preventing such a condition.
12. A method according to Claim 11 , wherein M+ is Na+.
13. A method of treating or preventing a condition caused by a bacterial infection in dogs and cats, comprising administering to the dog or cat a therapeutically effective amount of the pharmaceutical composition according to Claims 1-10.
14. A method according to Claims 11-13, wherein the condition is a skin, soft tissue or urinary tract bacterial infection.
15. A method according to Claims 11-14, wherein the condition or infection is caused by or complicated by Gram positive or Gram negative bacteria.
PCT/IB2002/004743 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs WO2003045435A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AU2002348986A AU2002348986B2 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
BRPI0214583A BRPI0214583B1 (en) 2001-11-30 2002-11-13 formulations comprising a cephalosporin compound and its uses in the treatment of bacterial infections in cats and dogs
DE60228749T DE60228749D1 (en) 2001-11-30 2002-11-13 COMPOSITIONS CONTAINING CEPHALOSPORIN COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BACTERIAL INFECTIONS IN DOGS AND CATS
IL16185102A IL161851A0 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in catsand dogs
MXPA04003724A MXPA04003724A (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs.
NZ532208A NZ532208A (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
JP2003546936A JP4689959B2 (en) 2001-11-30 2002-11-13 Formulations containing cephalosporin compounds and their use in the treatment of bacterial infections in dogs and cats
EP02781499A EP1448234B1 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use in treating bacterial infections in cats and dogs
CA002468708A CA2468708C (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
KR1020047008097A KR100621291B1 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
DK02781499T DK1448234T3 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use in the treatment of bacterial infections in cats and dogs
EA200400489A EA008503B1 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
IS7214A IS7214A (en) 2001-11-30 2004-04-07 Compositions comprising the cephalosporin compound and their use in the treatment of bacterial infections in cats and dogs
IL161851A IL161851A (en) 2001-11-30 2004-05-06 Formulations comprising a cephalosporin compound and their use for treating bacterial infections in cats and dogs
TNP2004000097A TNSN04097A1 (en) 2001-11-30 2004-05-28 FORMULATIONS COMPRISING A CEPHALOSPORIN AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS IN CATS AND DOGS.
HR20040487A HRP20040487A2 (en) 2001-11-30 2004-05-31 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
NO20042271A NO334818B1 (en) 2001-11-30 2004-06-01 Formulations containing a cephalosporin compound, seen extensively and their use in the treatment of bacterial infections in cats and dogs
HK05104040.7A HK1071292A1 (en) 2001-11-30 2005-05-13 Formulations comprising a cephalosporin compound

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33853601P 2001-11-30 2001-11-30
US60/338,536 2001-11-30
US39893202P 2002-07-26 2002-07-26
US60/398,932 2002-07-26

Publications (1)

Publication Number Publication Date
WO2003045435A1 true WO2003045435A1 (en) 2003-06-05

Family

ID=26991236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004743 WO2003045435A1 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs

Country Status (28)

Country Link
US (1) US7378408B2 (en)
EP (1) EP1448234B1 (en)
JP (1) JP4689959B2 (en)
KR (1) KR100621291B1 (en)
CN (1) CN100502873C (en)
AR (1) AR037595A1 (en)
AT (1) ATE406916T1 (en)
AU (1) AU2002348986B2 (en)
BR (1) BRPI0214583B1 (en)
CA (1) CA2468708C (en)
CY (1) CY1108437T1 (en)
DE (1) DE60228749D1 (en)
DK (1) DK1448234T3 (en)
EA (1) EA008503B1 (en)
ES (1) ES2307800T3 (en)
HK (1) HK1071292A1 (en)
HR (1) HRP20040487A2 (en)
IL (2) IL161851A0 (en)
IS (1) IS7214A (en)
MA (1) MA27085A1 (en)
MX (1) MXPA04003724A (en)
NO (1) NO334818B1 (en)
NZ (1) NZ532208A (en)
PL (1) PL212683B1 (en)
PT (1) PT1448234E (en)
TN (1) TNSN04097A1 (en)
TW (1) TWI248363B (en)
WO (1) WO2003045435A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656930A1 (en) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
US7303755B2 (en) 2002-08-01 2007-12-04 Zambon S.P.A. Pharmaceutical compositions with antibiotic activity
WO2009051626A1 (en) * 2007-10-18 2009-04-23 Janssen Pharmaceutica, N.V. Cephalosporin derivative formulation
WO2020008183A1 (en) 2018-07-02 2020-01-09 Norbook Laboratories Limited Intermediates in the synthesis of c3-substituted cephalosporins

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005002742T2 (en) * 2004-04-22 2008-01-24 Pfizer Products Inc., Groton METHOD FOR STABILIZING UNLOCATED CEFOVECIN SODIUM SALT
UA91205C2 (en) * 2004-12-17 2010-07-12 Венус Ремедиз Лимитед Antibiotic combinations for providing total solution to the treatment of infections
UA91208C2 (en) * 2005-02-14 2010-07-12 Венус Ремедиз Лимитед Pharmaceutical composition comprising antimicrobial glycopeptide and cephalosporin for therapy of drug resistant infective conditions
US20080318919A1 (en) * 2005-10-29 2008-12-25 Intervet International B.V. Cefquinome Compositions and Methods of Their Use
JP2011514902A (en) * 2008-03-04 2011-05-12 エラン・ファルマ・インターナショナル・リミテッド Stable liquid formulations of anti-infectives and controlled anti-infective regimens
CN101352422B (en) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 Tetrodotoxin lyophilized powder formulation for injection and preparation method thereof
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8784385B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen piercing implements and methods for piercing a substrate
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8256233B2 (en) 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
KR102226197B1 (en) * 2013-03-15 2021-03-11 머크 샤프 앤드 돔 코포레이션 Ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
PT3319596T (en) * 2015-07-09 2024-01-17 Uniwell Laboratories Llc Pharmaceutical compositions
RU2018112431A (en) 2015-09-07 2019-10-09 Мотида Фармасьютикал Ко., Лтд. LYOPHILIZED ALGINIC ACID
TW201920174A (en) 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
EP3687992A1 (en) 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivatives and production process thereof
EP3687504A1 (en) 2017-09-27 2020-08-05 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
CN109393004A (en) * 2018-09-28 2019-03-01 上海锦立保鲜科技有限公司 A method of vacuum thawing is realized using the free water sublimate of frozen product
KR20240105503A (en) * 2021-11-26 2024-07-05 아스테라스 세이야쿠 가부시키가이샤 Solid pharmaceutical composition containing indocyanine compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001695A1 (en) * 1990-07-24 1992-02-06 Beecham Group Plc Cephalosporins and homologues, preparations and pharmaceutical compositions
US6020329A (en) * 1990-07-24 2000-02-01 Pzifer Inc. Cephaloporins and homologues, preparations and pharmaceutical compositions
WO2002046198A1 (en) * 2000-12-04 2002-06-13 Pfizer Products Inc. Coupling process and intermediates useful for preparing cephalosphorins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002748A (en) 1976-01-19 1977-01-11 Eli Lilly And Company Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
JPS5711909A (en) 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS6045514A (en) 1983-08-22 1985-03-12 Shionogi & Co Ltd Stable antibacterial lyophilized pharmactical preparation
SE8500273D0 (en) * 1985-01-22 1985-01-22 Leo Ab NEW TRICYCLIC ASSOCIATIONS, COMPOSITIONS CONTAINING SUCH ASSOCIATIONS, MANUFACTURING PROCEDURES AND METHODS OF TREATMENT
US5138066A (en) 1987-08-14 1992-08-11 Hoffmann-La Roche, Inc. Intermediates for cephalosporins with sulfur-containing oxyimino side chain
ZA89829B (en) 1988-02-05 1990-10-31 Lilly Co Eli Crystalline b-lactam solvate
CA2024587A1 (en) * 1989-09-05 1991-03-06 Bernard Ecanow Drug delivery compositions based on biological cells or components thereof and methods
US6001997A (en) 1990-07-24 1999-12-14 Bateson; John Hargreaves Cephalosporins and homologues, preparations and pharmaceutical compositions
US5401842A (en) 1992-09-08 1995-03-28 Bristol-Myers Squibb Company Injectable compositions of a cephalosporin dihydrate salt
EP0664117A1 (en) * 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposome solutions
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
KR100312622B1 (en) * 1998-11-03 2002-02-28 김송배 Stabilized anticancer composition mainly composed of herbal medicine and its manufacturing method
JP2001199889A (en) * 1999-11-11 2001-07-24 Takeda Chem Ind Ltd Collunarium comprising annulated pyridazine derivative
EP1246668B1 (en) 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
GB0002835D0 (en) * 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
GB0019124D0 (en) 2000-08-03 2000-09-27 Pfizer Novel process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001695A1 (en) * 1990-07-24 1992-02-06 Beecham Group Plc Cephalosporins and homologues, preparations and pharmaceutical compositions
US6020329A (en) * 1990-07-24 2000-02-01 Pzifer Inc. Cephaloporins and homologues, preparations and pharmaceutical compositions
WO2002046198A1 (en) * 2000-12-04 2002-06-13 Pfizer Products Inc. Coupling process and intermediates useful for preparing cephalosphorins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BATESON J H ET AL: "NOVEL C-3 CYCLIC ETHER CEPHALOSPORINS AND THEIR ORALLY ABSORBED PRODRUG ESTERS", JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. TOKYO, JP, vol. 47, no. 2, 1 February 1994 (1994-02-01), pages 253 - 256, XP000670097, ISSN: 0021-8820 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303755B2 (en) 2002-08-01 2007-12-04 Zambon S.P.A. Pharmaceutical compositions with antibiotic activity
EP1656930A1 (en) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
WO2006050631A1 (en) 2004-11-10 2006-05-18 Basilea Pharmaceutica Ag Stabilized freeze-dried formulation for cephalosporin derivatives
AU2005304252B2 (en) * 2004-11-10 2009-07-16 Basilea Pharmaceutica Ag Stabilized freeze-dried formulation for cephalosporin derivatives
CN101056623B (en) * 2004-11-10 2011-04-06 巴斯利尔药物股份公司 Stabilized freeze-dried formulation for cephalosporin derivatives
EP2210592A3 (en) * 2004-11-10 2011-12-14 Basilea Pharmaceutica AG Stabilized Freeze-dried Formulation for Cephalosporin Derivatives
WO2009051626A1 (en) * 2007-10-18 2009-04-23 Janssen Pharmaceutica, N.V. Cephalosporin derivative formulation
WO2020008183A1 (en) 2018-07-02 2020-01-09 Norbook Laboratories Limited Intermediates in the synthesis of c3-substituted cephalosporins

Also Published As

Publication number Publication date
EP1448234B1 (en) 2008-09-03
PL212683B1 (en) 2012-11-30
JP4689959B2 (en) 2011-06-01
TWI248363B (en) 2006-02-01
HK1071292A1 (en) 2005-07-15
MXPA04003724A (en) 2005-04-08
US20030186957A1 (en) 2003-10-02
ES2307800T3 (en) 2008-12-01
EP1448234A1 (en) 2004-08-25
CN100502873C (en) 2009-06-24
PL370083A1 (en) 2005-05-16
CA2468708C (en) 2008-08-19
AR037595A1 (en) 2004-11-17
AU2002348986B2 (en) 2008-04-03
DK1448234T3 (en) 2008-11-03
BR0214583A (en) 2004-11-03
EA008503B1 (en) 2007-06-29
CN1604793A (en) 2005-04-06
AU2002348986A1 (en) 2003-06-10
TNSN04097A1 (en) 2006-06-01
BRPI0214583B1 (en) 2015-11-17
ATE406916T1 (en) 2008-09-15
PT1448234E (en) 2008-10-02
NZ532208A (en) 2007-01-26
JP2005511642A (en) 2005-04-28
CA2468708A1 (en) 2003-06-05
IS7214A (en) 2004-04-07
HRP20040487A2 (en) 2004-10-31
KR20040058345A (en) 2004-07-03
IL161851A (en) 2011-11-30
IL161851A0 (en) 2005-11-20
EA200400489A1 (en) 2004-10-28
CY1108437T1 (en) 2014-04-09
DE60228749D1 (en) 2008-10-16
TW200300351A (en) 2003-06-01
KR100621291B1 (en) 2006-09-13
MA27085A1 (en) 2004-12-20
NO20042271L (en) 2004-07-22
NO334818B1 (en) 2014-06-02
US7378408B2 (en) 2008-05-27

Similar Documents

Publication Publication Date Title
US7378408B2 (en) Methods of treatment and formulations of cephalosporin
JP7177314B2 (en) Ceftolozane antibiotic composition
US7115564B2 (en) Stable pharmaceutical compositions of dalbavancin and methods of administration
ZA200209419B (en) Glycopeptide phosphonate derivatives.
KR100403497B1 (en) Carbapenem antibiotic
CN115581700A (en) Pharmaceutical composition containing cefotaxime sulbactam or cefotaxime tazobactam with stable quality and high antibacterial activity
US5776912A (en) Lipophilic oligosaccharide antibiotic compositions
NZ551403A (en) Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
ZA200403933B (en) Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
EP1671635B1 (en) Noncrystalline antibacterial composition containing cefditoren pivoxil
EP0169700B1 (en) Improved pharmaceutical formulations for ceftazidime
EP1326608B1 (en) Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers
US20030149013A1 (en) Methods of treating bacterial infections in dogs and cats
AU2002348985A1 (en) Methods of treating bacterial infections in dogs and cats
US20020161003A1 (en) Method and compositions for the eradication and control of methicillin-resistant staphylococcus aureus bacteria and the prevention of the development of antibiotic drug resistance in said bacteria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 532208

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002348986

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/003724

Country of ref document: MX

Ref document number: 1053/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200400489

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 161851

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002781499

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-423/04

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 20028229258

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004/03933

Country of ref document: ZA

Ref document number: 200403933

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500726

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1020047008097

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003546936

Country of ref document: JP

Ref document number: 2468708

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: P20040487A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 2002781499

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002781499

Country of ref document: EP